RxDoctor Payments Data

David Gothelf, DO

Family Medicine · Henderson, NVNPI 1023057296

Payments from drug & device makers

$3,764in general payments, 2019–2025

Across 222 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$802
  • Boehringer Ingelheim$628
  • Novo Nordisk$309
  • Pfizer$220
  • Astellas Pharma US Inc$180
  • Johnson & Johnson$130
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,764100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,764 in reported general payments places this provider in the 85th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$32,478
Medicare patients
185
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$96,937
XareltoRivaroxaban25$28,643
Spiriva HandihalerTiotropium Bromide16$23,333
SymbicortBudesonide/Formoterol Fumarate44$20,396
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,970
JanuviaSitagliptin Phosphate16$13,463
Albuterol Sulfate HfaAlbuterol Sulfate153$6,741
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$6,459
Atorvastatin Calcium671$5,001
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen166$4,723
Omeprazole298$4,121
Levothyroxine Sodium433$3,635
Wixela InhubFluticasone Propion/Salmeterol23$3,281
Rosuvastatin Calcium315$3,079
Tramadol Hcl172$2,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$220$96,93776 claims
Johnson & JohnsonXarelto$130$28,64325 claims
AstraZenecaSymbicort$802$20,39644 claims
GSKTrelegy Ellipta$74$13,97016 claims
MerckJanuvia$32$13,46316 claims
AbbVieSynthroid$126$2,54937 claims
Sanofi-aventis U.S. LLCLantus$83$2,10212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 902 family medicine providers in Nevada.

Other family medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →